JP2021042159A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021042159A5 JP2021042159A5 JP2019165017A JP2019165017A JP2021042159A5 JP 2021042159 A5 JP2021042159 A5 JP 2021042159A5 JP 2019165017 A JP2019165017 A JP 2019165017A JP 2019165017 A JP2019165017 A JP 2019165017A JP 2021042159 A5 JP2021042159 A5 JP 2021042159A5
- Authority
- JP
- Japan
- Prior art keywords
- cyclodextrin
- active compound
- pharmaceutically active
- derivative
- mol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920000858 Cyclodextrin Polymers 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 12
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 10
- 235000019658 bitter taste Nutrition 0.000 claims 6
- 239000001116 FEMA 4028 Substances 0.000 claims 3
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical group OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims 3
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims 3
- 229960004853 betadex Drugs 0.000 claims 3
- 229960002496 duloxetine hydrochloride Drugs 0.000 claims 3
- JFTURWWGPMTABQ-UHFFFAOYSA-N n,n-dimethyl-3-naphthalen-1-yloxy-3-thiophen-2-ylpropan-1-amine Chemical compound C=1C=CC2=CC=CC=C2C=1OC(CCN(C)C)C1=CC=CS1 JFTURWWGPMTABQ-UHFFFAOYSA-N 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000012669 liquid formulation Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
Claims (9)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019165017A JP7390830B2 (en) | 2019-09-11 | 2019-09-11 | Bitterness suppressor and method for suppressing bitterness of pharmaceutically active compounds |
| JP2023197093A JP2024009146A (en) | 2019-09-11 | 2023-11-21 | Agent and method for inhibiting bitterness of pharmaceutical active compound |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019165017A JP7390830B2 (en) | 2019-09-11 | 2019-09-11 | Bitterness suppressor and method for suppressing bitterness of pharmaceutically active compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023197093A Division JP2024009146A (en) | 2019-09-11 | 2023-11-21 | Agent and method for inhibiting bitterness of pharmaceutical active compound |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021042159A JP2021042159A (en) | 2021-03-18 |
| JP2021042159A5 true JP2021042159A5 (en) | 2022-09-15 |
| JP7390830B2 JP7390830B2 (en) | 2023-12-04 |
Family
ID=74863742
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019165017A Active JP7390830B2 (en) | 2019-09-11 | 2019-09-11 | Bitterness suppressor and method for suppressing bitterness of pharmaceutically active compounds |
| JP2023197093A Pending JP2024009146A (en) | 2019-09-11 | 2023-11-21 | Agent and method for inhibiting bitterness of pharmaceutical active compound |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023197093A Pending JP2024009146A (en) | 2019-09-11 | 2023-11-21 | Agent and method for inhibiting bitterness of pharmaceutical active compound |
Country Status (1)
| Country | Link |
|---|---|
| JP (2) | JP7390830B2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230173533A (en) * | 2022-06-17 | 2023-12-27 | 주식회사 코아팜바이오 | New composition of orodispersible powder |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1149991C (en) | 1998-09-15 | 2004-05-19 | 伊莱利利公司 | Treatment of persistent pain |
| EP1904039A2 (en) | 2005-06-20 | 2008-04-02 | Cadila Healthcare Ltd. | Controlled release dosage formulation of duloxetine |
| US20100215740A1 (en) | 2007-10-10 | 2010-08-26 | Rubicon Research Private Limited | Taste-masked orally disintegrating tablets of memantine hydrochloride |
| US8758779B2 (en) | 2009-06-25 | 2014-06-24 | Wockhardt Ltd. | Pharmaceutical composition of duloxetine |
| CN102579403B (en) | 2011-12-26 | 2013-08-21 | 天津市嵩锐医药科技有限公司 | Duloxetine hydrochloride drug composition |
| US11266658B2 (en) | 2017-03-03 | 2022-03-08 | Ctc Bio, Inc. | Preparation, comprising inclusion complex of varenicline or pharmaceutically acceptable salt thereof, for oral administration |
-
2019
- 2019-09-11 JP JP2019165017A patent/JP7390830B2/en active Active
-
2023
- 2023-11-21 JP JP2023197093A patent/JP2024009146A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008513467A5 (en) | ||
| JP2017105763A5 (en) | ||
| JP2007302683A5 (en) | ||
| JP2014129360A5 (en) | ||
| NZ597109A (en) | Tablet composition having favorable dissolution property useful as an anticoagulant | |
| JP2010513478A5 (en) | ||
| TW200716202A (en) | Pediatric formulation of topiramate | |
| JP2008044957A (en) | Antimicotic nail varnish composition | |
| WO2014144130A3 (en) | Pharmaceutical composition comprising an ampk activator and a serotonergic agent and methods of use thereof | |
| JP2012092123A5 (en) | ||
| JP2010090168A5 (en) | ||
| RS51585B (en) | Aerosol formulation for inhalation, containing an anticholinergic agent | |
| WO2008057802A3 (en) | Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same | |
| BR112018011777A2 (en) | fenfluramine compositions and methods for preparing them | |
| AR068044A1 (en) | CATECOLAMINE DERIVATIVES AND DRUGS OF THE SAME | |
| NO20062051L (en) | Pharmaceutical active ingredient-containing formulation with coating | |
| JP2008515980A5 (en) | ||
| EA201990501A1 (en) | PHARMACEUTICAL COMPOSITION | |
| JP2015514739A5 (en) | ||
| JP2021042159A5 (en) | ||
| NO20055601L (en) | Pharmaceutical preparation in the form of a hydrogel for transdermal administration of active ingredients | |
| AR085273A1 (en) | PROPELLENT FREE LIQUID FORMULATION THAT INCLUDES AN ANTIMUSCARINIC DRUG | |
| JP2019151627A5 (en) | ||
| NO20083759L (en) | Dosage aerosols for administration of pharmaceutical compositions | |
| WO2016005995A3 (en) | Glycol free stable liquid compositions of bendamustine |